2025-04-23 - Analysis Report
## Natera Inc. (NTRA) Stock Report

**0. Summary Statistics:**

NTRA has significantly outperformed the S&P 500 (VOO) over the period analyzed. While showing volatility, recent financial data suggests improving revenue and profitability, though profitability remains negative.  Short-term price action indicates some downward pressure, but long-term potential remains positive, as indicated by a high expected return relative to the S&P 500.

**1. Performance Comparison:**

Natera Inc. (NTRA) is a biotechnology company focused on genetic testing.

* **Cumulative Return (NTRA):** 119.69%
* **Cumulative Return (VOO):** 70.98%
* **Return Difference:** 48.71% (NTRA outperformed VOO by 48.71%)
* **Relative Divergence:** 14.5% (This indicates NTRA's performance relative to VOO is in the higher range of historical divergence, but not exceptionally high.)


**Alpha and Beta Analysis:**

The provided data shows high volatility in NTRA's performance, with significant year-over-year swings in CAGR (Compound Annual Growth Rate) and MDD (Maximum Drawdown).  Alpha, a measure of excess return relative to the benchmark, fluctuates considerably, while Beta, a measure of market sensitivity, generally remains above 1, suggesting higher volatility than the market.

| Year       | CAGR    | MDD     | Alpha  | Beta | Cap(B) |
|------------|---------|---------|--------|-------|--------|
| 2015-2017  | -6.0%   | 62.4%   | -0.1   | 1.2   |        |
| 2016-2018  | 29.0%   | 80.1%   | 0.0    | 1.9   |        |
| 2017-2019  | 159.0%  | 80.1%   | 1.3    | 4.7   |        |
| 2018-2020  | 530.0%  | 80.1%   | 0.7    | 13.8  |        |
| 2019-2021  | 355.0%  | 62.9%   | 0.3    | 12.9  |        |
| 2020-2022  | -119.0% | 62.9%   | 0.3    | 5.6   |        |
| 2021-2023  | -482.0% | 69.9%   | 1.3    | 8.7   |        |
| 2022-2024  | -75.0%  | 70.6%   | 1.3    | 21.9  |        |
| 2023-2025  | 68.0%   | 72.8%   | 0.9    | 20.0  |        |


**2. Recent Price Action:**

* **Closing Price:** $144.62
* **5-Day Moving Average:** $147.37
* **20-Day Moving Average:** $144.68
* **60-Day Moving Average:** $154.44

The price is slightly below the 20-day moving average and considerably below the 60-day moving average, suggesting a potential downward trend in the short term.  The recent price change shows a small increase (+1.68), which is not considered a significant upward or downward swing.

**3. Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.435 (Medium Risk)
* **RSI:** 52.79 (Slightly above the neutral level of 50, suggesting neither overbought nor oversold conditions.)
* **PPO:** 0.49 (Positive value suggests a potential bullish trend.)
* **20-Day Relative Divergence Change:** -0.5 (Indicates a recent short-term downward trend.)
* **Expected Return:** 114.0% (This is a high expected return relative to the S&P 500 over the long term, suggesting strong potential, but should be considered alongside the high risk.)

The recent price increase is modest and doesn't significantly alter the overall picture indicated by the moving averages and technical indicators.


**4. Recent Earnings Analysis:**

| Date        | EPS     | Revenue       |
|-------------|---------|---------------|
| 2024-11-12  | -$0.26  | $0.44B        |
| 2024-08-09  | -$0.30  | $0.41B        |
| 2024-05-10  | -$0.56  | $0.37B        |
| 2023-11-09  | -$0.95  | $0.27B        |
| 2024-11-12  | -$0.95  | $0.27B        | *(Duplicate entry, likely an error)*


Revenue is showing a clear upward trend.  However, EPS remains negative throughout the period, indicating ongoing losses.  The duplicate entry needs clarification.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue  | Profit Margin |
|-------------|----------|---------------|
| 2024-12-31  | $0.48B   | 62.94%        |
| 2024-09-30  | $0.44B   | 61.79%        |
| 2024-06-30  | $0.41B   | 58.83%        |
| 2024-03-31  | $0.37B   | 56.72%        |
| 2023-12-31  | $0.31B   | 51.38%        |

Revenue is steadily increasing. Profit margins are also increasing, although the company is still not profitable (as reflected in negative EPS).

**Capital and Profitability:**

| Quarter     | Equity   | ROE         |
|-------------|----------|-------------|
| 2024-12-31  | $1.20B   | -4.50%      |
| 2024-09-30  | $0.88B   | -3.60%      |
| 2024-06-30  | $0.84B   | -4.48%      |
| 2024-03-31  | $0.79B   | -8.51%      |
| 2023-12-31  | $0.77B   | -10.20%     |

Equity is increasing, but ROE (Return on Equity) remains negative, highlighting the company's persistent unprofitability despite revenue growth.


**6. Overall Analysis:**

NTRA shows strong potential for long-term growth, indicated by a high expected return compared to the S&P 500.  However,  the company is currently unprofitable, despite increasing revenue and improving profit margins. The high volatility and significant drawdowns demonstrate substantial risk.  Investors should carefully consider the high risk associated with NTRA's high Beta and fluctuating performance before making any investment decisions.  Further investigation into the reasons for ongoing losses and the consistency of the revenue growth trend is crucial.  The duplicated earnings data requires clarification.  Long-term investors might consider dollar-cost averaging to mitigate risk given the volatility.
